摘要
目的评价丁苯酞氯化钠注射液和依达拉奉右莰醇注射用浓溶液用于缺血性脑卒中的疗效和经济性。方法回顾性分析2020年1月至2021年9月于牡丹江医学院附属第二医院入院治疗的440例缺血性脑卒中患者临床资料。根据用药方案不同把患者分为丁苯酞组(n=215)和依达拉奉组(n=225)。倾向性匹配前后,分别比较两组的一般临床资料及总有效率差异。通过两组药物的不良反应发生率,比较临床安全性。采用多因素logistic回归分析控制混杂因素,比较两组药物的效果。再比较两组药物直接医疗成本,并进行广义线性回归进行分析。结果倾向性匹配评分前,两组患者高密度脂蛋白比较,差异有统计学意义(P<0.05);倾向性匹配评分后,一般资料差异比较均无统计学意义(P>0.05)。倾向性匹配前后,两组临床有效率比较,差异均无统计学意义(P>0.05)。多因素logistic回归分析结果可知,两种药物治疗效果差异无统计学意义,与基础分析结果相一致;年龄、高血压为缺血性脑卒中患者疗效的影响因素(P<0.05)。丁苯酞组和依达拉奉组的不良反应发生率比较差异无统计学意义(P>0.05),临床安全性相当。两组直接医疗成本比较差异无统计学意义(P>0.05);广义线性模型回归分析结果可知,丁苯酞组成本低于依达拉奉组,差异有统计学意义(P<0.05)。结论丁苯酞氯化钠注射液和依达拉奉右莰醇注射用浓溶液治疗缺血性脑卒中临床疗效和安全性相当,丁苯酞氯化钠注射液成本较低更具有经济性。
Objective To evaluate the efficacy and economy of butylphthalide and sodium chloride injection and edaravone and dexborneol concentrated solutionfor injection for ischemic stroke.Methods A retrospective analysis was conducted on the clinical data of 440 patients with ischemic stroke admitted to the Second Affiliated Hospital of Mudanjiang Medical University from January 2020 to September 2021.According to different medication regimens,the patients were divided into a butylphthalide group(n=215)and an edaravone group(n=225).The differences in general clinical data and total effective rate between the two groups were compared before and after propensity matching.Clinical safety was determined by comparing the incidence of adverse drug reactions of the two groups.Multivariate logistic regression analysis was used to control confounding factors and compare the effectiveness of drugs in the two groups.The direct medical costs of drugs in the two groups were compared and a generalized linear regression analysis was performed.Results Before propensity matching scoring,there was statistically significant difference in high-density lipoprotein between the two groups(P<0.05).After propensity matching scoring,there was no statistically significant difference in general data(P>0.05).There was no statistically significant difference in clinical efficacy between the two groups before and after propensity matching(P>0.05).The results of multivariate logistic regressionanalysis showed that there was no significant difference in the therapeutic effects of the two drugs,which were consistent with the basic analysis results.Age and hypertension was the influencing factor for the efficacy of patients with ischemic stroke(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the butylphthalide group and the edaravone group(P>0.05),and the clinical safety was comparable.The direct medical costs of the two groups showed no statistically significant difference(P>0.05).The results of the
作者
曲政
李龙
耿毅楠
吴艳丽
魏威
张本卓
马占荣
黄俊荣
王彬
QU Zheng;LI Long;GENG Yinan;WU Yanli;WEI Wei;ZHANG Benzhuo;MA Zhanrong;HUANG Junrong;WANG Bin(Graduate School,Mudanjiang Medical University,Heilongjiang,Mudanjiang 157011,China;Department of Pharmacy,the Second Affiliated Hospital of Mudanjiang Medical University,Heilongjiang,Mudanjiang 157010,China)
出处
《中国医药科学》
2023年第16期11-16,共6页
China Medicine And Pharmacy
基金
黑龙江省省属高等学校基本科研业务费科研项目(2018-KYYWFMY-0082)。
关键词
丁苯酞氯化钠注射液
依达拉奉右莰醇
缺血性脑卒中
成本效果
Butylphthalide and sodium chloride injection
Edaravone and dexborneol
Ischemic stroke
Cost effectiveness
